JP5593234B2 - ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法 - Google Patents

ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法 Download PDF

Info

Publication number
JP5593234B2
JP5593234B2 JP2010550004A JP2010550004A JP5593234B2 JP 5593234 B2 JP5593234 B2 JP 5593234B2 JP 2010550004 A JP2010550004 A JP 2010550004A JP 2010550004 A JP2010550004 A JP 2010550004A JP 5593234 B2 JP5593234 B2 JP 5593234B2
Authority
JP
Japan
Prior art keywords
group
cancer
tumor
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010550004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513438A5 (OSRAM
JP2011513438A (ja
Inventor
クオホワ パン
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2011513438A publication Critical patent/JP2011513438A/ja
Publication of JP2011513438A5 publication Critical patent/JP2011513438A5/ja
Application granted granted Critical
Publication of JP5593234B2 publication Critical patent/JP5593234B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010550004A 2008-03-11 2009-03-10 ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法 Expired - Fee Related JP5593234B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US6890008P 2008-03-11 2008-03-11
US61/068,900 2008-03-11
US12690908P 2008-05-08 2008-05-08
US61/126,909 2008-05-08
US19035608P 2008-08-28 2008-08-28
US61/190,356 2008-08-28
US11823108P 2008-11-26 2008-11-26
US61/118,231 2008-11-26
PCT/CA2009/000286 WO2009111868A1 (en) 2008-03-11 2009-03-10 Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist

Publications (3)

Publication Number Publication Date
JP2011513438A JP2011513438A (ja) 2011-04-28
JP2011513438A5 JP2011513438A5 (OSRAM) 2012-04-19
JP5593234B2 true JP5593234B2 (ja) 2014-09-17

Family

ID=41064694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550004A Expired - Fee Related JP5593234B2 (ja) 2008-03-11 2009-03-10 ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法

Country Status (7)

Country Link
US (1) US8765791B2 (OSRAM)
EP (1) EP2262499B1 (OSRAM)
JP (1) JP5593234B2 (OSRAM)
CN (1) CN102014900B (OSRAM)
AU (1) AU2009225189B2 (OSRAM)
CA (1) CA2717904C (OSRAM)
WO (1) WO2009111868A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
WO2013101617A1 (en) * 2011-12-29 2013-07-04 Purdue Research Foundation Method for assessing a liver of a patient having a chronic hepatitis b virus infection
MX357763B (es) 2013-10-18 2018-07-23 Univ Health Network Tratamiento para cancer pancreatico.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
WO2001095856A2 (en) * 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
HRP20040213A2 (en) 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2492225A1 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
EP1635832A2 (en) * 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US20050288279A1 (en) * 2004-06-24 2005-12-29 Rozman Karl K Phenothiazine derivatives and their method of use
CN101336244B (zh) 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物

Also Published As

Publication number Publication date
AU2009225189B2 (en) 2012-08-02
WO2009111868A1 (en) 2009-09-17
EP2262499B1 (en) 2016-12-21
US20110112102A1 (en) 2011-05-12
CA2717904C (en) 2016-08-30
CA2717904A1 (en) 2009-09-17
CN102014900A (zh) 2011-04-13
AU2009225189A1 (en) 2009-09-17
EP2262499A1 (en) 2010-12-22
US8765791B2 (en) 2014-07-01
EP2262499A4 (en) 2012-03-21
JP2011513438A (ja) 2011-04-28
CN102014900B (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
US20220370422A1 (en) Compounds and compositions for treating hematological disorders
US20240358687A1 (en) Use of nox inhibitors for treatment of cancer
JP5593234B2 (ja) ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法
US11492362B1 (en) Pyridine derivatives for the treatment of hyperproliferative diseases
HK40113079A (en) Antineoplastic combinations of neratinib and capecitabine
HK1152248B (en) Mk-0557 for use in the treatment of cancer
HK1152248A (en) Mk-0557 for use in the treatment of cancer
HK1239521A1 (en) Antineoplastic combinations of neratinib and capecitabine
HK1228780A1 (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HK1239521B (en) Antineoplastic combinations of neratinib and capecitabine
HK1158077A (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140804

R150 Certificate of patent or registration of utility model

Ref document number: 5593234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees